Treatment of metastatic breast cancer in EU: Analysis of market research data from 4Q2013 till 3Q2014

Despite the recommendation provided by current ESMO guidelines on mBC treatments, indicating the sequential use of single cytotoxic agents is a considerable alternative to standard multidrug chemotherapy regimens, marketing research data suggests this may not be reflected in EU prescribing behavior.